Pluristyx, Inc.

Announcing the Manufacture of the PSXi013 GMP Master Cell Bank! We are excited to announce the successful manufacture of the PSXi013 Master Cell Bank under GMP-compliant conditions in an ISO7 cleanroom at an FDA-certified facility. This milestone brings us one step closer to providing high-quality iPSC lines for therapeutic development and research.   The GMP PSXi013 line is available at Passage 10 and has been extensively characterized in extended culture conditions to confirm genomic stability.  Both clones and a gene-editing compatible pool are available for immediate evaluation and licensing. PSXi013 will be accompanied by a Drug Master File on record with the US FDA and provides a low passage and reliable starting material for our FailSafe® and hypoimmune platform edits, or your cutting-edge modifications and product development.  This line is also available to Advanced Regenerative Manufacturing Institute (ARMI) | BioFabUSA Members for use in the Tissue Foundry for scale-up and automation assistance.  Interested in learning more? Connect with Benjamin Fryer or Brian Hawkins at Meeting on the Mesa from Oct 7-9 to explore licensing opportunities and discuss how these cells can accelerate your research and development. https://lnkd.in/eCvNmYVy #MasterCellBank #iPSCCells #RegenerativeMedicine #CellTherapy #StemGenomics #ARMI #Pluristyx #CGMesa24 #panCELLa

Ben is in Boston! Please reach out to schedule a meeting if you would like to connect with him at the iPSC Drug Development and Manufacturing Summit. https://lnkd.in/eCvNmYVy

Pluristyx has escaped from the lab!  Catch us if you can at the nearest event: The Pluristyx team is gearing up for several great opportunities to connect and collaborate!  We are thrilled to announce that we will be attending the following events: iPSC Drug Development & Manufacturing Summit October 1 - 3: Boston, MA, USA Benjamin Fryer ISSCR - International Symposium October 2 - 4: Copenhagen, Denmark Peter Yu ARM Meeting on the Mesa October 7 - 9: Phoenix, AZ, USA Pluristyx, Inc. As pioneers in cell therapy solutions, we look forward to engaging with industry experts, sharing insights, and exploring partnerships to drive innovation forward. Whether you’re looking to accelerate your research, streamline your manufacturing process, or explore new strategic partnerships, we'd love to meet with you! Let's connect—reach out to schedule a meeting to learn more about how Pluristyx is bringing Tomorrow’s Cell Therapies, Today®. https://lnkd.in/eCvNmYVy #CellTherapy #Innovation #Pluristyx #Biotech #EventNetworking #PartneringForSuccess #CellAndGeneTherapy

That's a Wrap, PluriCon 2024! A huge thank you to everyone who made the PluriCon conference in Seattle on September 10, 2024, such a memorable event! We sincerely appreciate all our speakers, sponsors, and attendees who contributed to the event's success. It was an honor to have so many passionate professionals, innovators, and thought leaders in our field in the same room sharing their perspective. Your insights and enthusiasm truly made the conference a success.    We look forward to continuing our conversations and exploring new opportunities with everyone. To that end, we will be posting highlights of the conference discussion in the upcoming weeks and look forward to discussion. Let’s keep the momentum going and work together to drive even more innovations to bring Tomorrow's Cell Therapies, Today! #Pluristyx #panCELLaPlatform #iPSC #PluriCon #stemcelltherapy 

Pluristyx, Inc. is thrilled to announce a new collaboration with Dr. Aaron Goldman’s laboratory at Mass General Brigham, under our innovative PluriPartners program. This partnership aims to propel cutting-edge stem cell research by offering academic institutions access to Pluristyx’s advanced tools and technologies at specially reduced rates. Through the PluriPartners program, Dr. Goldman’s lab will have access to several of Pluristyx's pioneering resources, including: 💠 RUO and GMP iPSC lines: Reprogrammed using Pluristyx’s proprietary mRNA technology, ensuring high quality and reliability. 💠 B2M/CIITA KO Failsafe Hypoimmune Cells: Equipped with a drug-inducible kill switch, these cells represent a backbone to build a hypoimmune strategy. 💠 DOE Kit for Customized Cryopreservation Solutions: Tailored solutions for the cryopreservation of cells, designed to optimize cell viability and functionality. Pluristyx is committed to supporting the academic community and fostering breakthroughs in regenerative medicine. This collaboration underscores our dedication to accelerating scientific discoveries through strategic partnerships.   For more information about the PluriPartners program or the Pluristyx portfolio, please visit https://pluristyx.com/.

The world's largest stem cell research conference #ISSCR2024 wrapped up in Germany last week. The conference featured significant exciting advances in clinical advancement of induced pluripotent stem cell (iPSC) derived therapies. Significant strides were shared towards treatments for Type 1 diabetes, Parkinson's Disease, acute and chronic liver diseases, as well as in bioprinting tissues and organs.   In order to achieve these breakthrough therapies issues around the scaled commercial manufacturing, stem cell handling, culture techniques, and characterization of cells and products to ensure the safety and efficacy of therapies were hot topics of discussion. Pluristyx, Inc. was honored to join our partner BioLamina to discuss several issues related to raw materials and the crucial importance of standardized culture and matrix reagents. We also highlighted our use of Stem Genomics' iCS Digital assay and 20q FISH in our standard characterization approach, enhancing the early and sensitive detection of genomic instability at a resolution higher than available with only traditional G-band karyology. #celltherapy #stemcells #iPSC

Another partnership completed. We are working with Pluristyx to make the best clinical-grade iPSCs. Benjamin Fryer Brian Hawkins You guys do amazing work! #ipsc #celltherapy

Meet Jason Carstens, our Chief Operating Officer and Co-Founder at Pluristyx, Inc. With over 25 years experience in biotech, Jason is one of the driving forces behind Pluristyx process development and manufacturing. 💠 Prior to starting Pluristyx, Jason was an independent consultant, guiding small biotech firms and large pharma companies through BLA regulatory submissions and cell therapy projects. 💠 He’s also been the VP of Manufacturing and Development at Nohla Therapeutics and participated in the groundbreaking research at the Fred Hutchinson Cancer Research Center, working on the some of the first CAR T-cell therapies, TIL, and gene-modified stem cell therapies that were ever used to treat patients.  💠 Jason also spent 13 years at CMC Biologics, leading Upstream Process Development and tackling over 50 unique projects. 💠 Jason holds a PhD in Chemical Engineering from UC Berkeley and a BS in Chemical Engineering from the University of Washington.

Pluristyx, Inc. is thrilled to be working with Humacyte to pave the way for groundbreaking advancements in insulin-dependant diabetes treatment.   Under this partnership, Humacyte has licensed Pluristyx’s clinical-grade PluriBank™ induced pluripotent stem cell (iPSC) line for use in their BioVascular Pancreas (BVP™) program. As part of the program, Humacyte intends to implant islet cells derived from this iPSC line into their proprietary Acellular Tissue Engineered Vessels (ATEV™).   The partnership also provides access to Pluristyx’s panCELLa™ platform, which enables the creation of “hypoimmune” cells with a drug-inducible kill-switch designed for safe clinical implantation. Pluristyx will be performing custom clinical gene editing on the iPSC line to generate this universal line.   This agreement highlights Pluristyx’s continued commitment to bringing Tomorrow's Cell Therapies, Today®, by ensuring safety and efficacy through our PluriBank™ cell lines and panCELLa™ platform.   Learn more about the partnership here: https://lnkd.in/gTdQAQZj

Pluristyx, Inc. is excited to announce the launch of our new panCELLa platform stem cell lines - iPSCs engineered with Failsafe®, a commercially available drug-inducible safety switch. Currently available lines include our PSXi013 with: 💠 Failsafe® 💠 Failsafe® B2M/CIITA knockout 💠 Unedited Control   These lines are RNA reprogrammed and provide an RUO test version of our clinical grade line and proprietary genetic Failsafe® engineering. Clinical grade versions are available upon request. Find out more at (https://lnkd.in/eCvNmYVy) or connect with our Chief Technology Officer, Dr. Brian Hawkins and Director Sales & Marketing Peter Yu at #ISSCR2024.